Wang D, Lai L H, Yan P, Dong P S
Department of Cardiovascular Medicine, The First Affiliated Hospital of the College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
J Biol Regul Homeost Agents. 2017 Jan-Mar;31(1):133-139.
This study aimed to investigate the correlation between blood asymmetric dimethylarginine (ADMA) and the complications of patients with cardiovascular diseases through studying the level changes of ADMA, endothelial nitric oxide synthase (eNOS) and NO. Two hundred research subjects with small differences in gender ratio and age, including 50 patients with hypertension combined with myocardial infarction, 50 patients with hypertension, 50 patients with myocardial infarction and 50 healthy normal controls, were enrolled. Relevant basic indexes were measured and recorded; the blood ADMA levels of all the research subjects were detected using high pressure liquid chromatography (HPLC) within the required time. Furthermore, the levels of eNOS and NO were detected using enzyme-linked immunosorbent assay and the relevant information, such as blood pressure, was recorded. The comparison and analysis results of data obtained through detection demonstrated that the subjects in the four groups were well comparable. It was found that the myocardial infarction combined with hypertension group had a much higher serum ADMA level and relatively low levels of eNOS and NO compared to those of the other three groups; the myocardial infarction group and the hypertension group had a much higher serum ADMA level compared to that of the healthy control group and the two groups had much lower levels of eNOS and NO. Moreover, the serum ADMA level was in a positive correlation with the severity of cardiovascular diseases and it showed a significant difference in patients with different severity of hypertension. The change of blood ADMA level can induce acute myocardial infarction as well as the occurrence of cardiovascular disease-associated complications.
本研究旨在通过研究不对称二甲基精氨酸(ADMA)、内皮型一氧化氮合酶(eNOS)和一氧化氮(NO)的水平变化,探讨血液中ADMA与心血管疾病患者并发症之间的相关性。招募了200名性别比例和年龄差异较小的研究对象,包括50例高血压合并心肌梗死患者、50例高血压患者、50例心肌梗死患者和50例健康正常对照者。测量并记录相关基础指标;在规定时间内使用高压液相色谱法(HPLC)检测所有研究对象的血液ADMA水平。此外,采用酶联免疫吸附测定法检测eNOS和NO水平,并记录血压等相关信息。检测所得数据的比较分析结果表明,四组研究对象具有良好的可比性。结果发现,与其他三组相比,心肌梗死合并高血压组的血清ADMA水平高得多,而eNOS和NO水平相对较低;心肌梗死组和高血压组的血清ADMA水平比健康对照组高得多,且两组的eNOS和NO水平低得多。此外,血清ADMA水平与心血管疾病的严重程度呈正相关,在不同严重程度的高血压患者中存在显著差异。血液ADMA水平的变化可诱发急性心肌梗死以及心血管疾病相关并发症的发生。